Your browser doesn't support javascript.
loading
Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental Phenotypes.
Verheyen, An; Diels, Annick; Reumers, Joke; Van Hoorde, Kirsten; Van den Wyngaert, Ilse; van Outryve d'Ydewalle, Constantin; De Bondt, An; Kuijlaars, Jacobine; De Muynck, Louis; De Hoogt, Ronald; Bretteville, Alexis; Jaensch, Steffen; Buist, Arjan; Cabrera-Socorro, Alfredo; Wray, Selina; Ebneth, Andreas; Roevens, Peter; Royaux, Ines; Peeters, Pieter J.
Afiliação
  • Verheyen A; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium. Electronic address: averhey1@its.jnj.com.
  • Diels A; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Reumers J; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Van Hoorde K; Open Analytics NV, Antwerpen 2600, Belgium.
  • Van den Wyngaert I; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • van Outryve d'Ydewalle C; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • De Bondt A; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Kuijlaars J; Hasselt University, Biomedical Research Institute, Diepenbeek 3590, Belgium.
  • De Muynck L; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • De Hoogt R; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Bretteville A; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Jaensch S; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Buist A; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Cabrera-Socorro A; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Wray S; Department of Molecular Neuroscience, Institute of Neurology, University College London, London WC1N 1PJ, UK.
  • Ebneth A; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Roevens P; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Royaux I; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Peeters PJ; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V, Turnhoutseweg 30, Beerse 2340, Belgium.
Stem Cell Reports ; 11(2): 363-379, 2018 08 14.
Article em En | MEDLINE | ID: mdl-30057263
ABSTRACT
Tauopathies such as frontotemporal dementia (FTD) remain incurable to date, partially due to the lack of translational in vitro disease models. The MAPT gene, encoding the microtubule-associated protein tau, has been shown to play an important role in FTD pathogenesis. Therefore, we used zinc finger nucleases to introduce two MAPT mutations into healthy donor induced pluripotent stem cells (iPSCs). The IVS10+16 mutation increases the expression of 4R tau, while the P301S mutation is pro-aggregant. Whole-transcriptome analysis of MAPT IVS10+16 neurons reveals neuronal subtype differences, reduced neural progenitor proliferation potential, and aberrant WNT/SHH signaling. Notably, these neurodevelopmental phenotypes could be recapitulated in neurons from patients carrying the MAPT IVS10+16 mutation. Moreover, the additional pro-aggregant P301S mutation revealed additional phenotypes, such as an increased calcium burst frequency, reduced lysosomal acidity, tau oligomerization, and neurodegeneration. This series of iPSCs could serve as a platform to unravel a potential link between pathogenic 4R tau and FTD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article